Stock DNLI DENALI THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Real-time Estimate Cboe BZX
Other stock markets
 20:51:27 26/06/2024 BST 		5-day change 1st Jan Change
21.99 USD -1.79% Intraday chart for Denali Therapeutics Inc. +1.50% +1.21%
06-13 Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors and Chairperson of Audit Committee CI
06-03 Denali Therapeutics' Enzyme Replacement Therapy Picked for FDA's START Pilot Program; Shares Rise MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer
AQ
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
GL
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GL
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
GL
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
AQ
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
GL
Denali Therapeutics Announces $500 million Private Placement Equity Financing
GL
Denali Therapeutics Announces $500 million Private Placement Equity Financing
AQ
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
GL
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
AQ
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
GL
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
AQ
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
GL
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
AQ
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
GL
MOMENTUM IN ALZHEIMER'S RESEARCH GUIDED BY THE BIOLOGY OF AGING TO BE HIGHLIGHTED IN SESSION MODERATED BY ALZHEIMER'S DRUG DISCOVERY FOUNDATION AT 2023 CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE
AQ
Metachromatic Leukodystrophy Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
ProFound Therapeutics Expands Leadership Team with Appointment of Klaus Urbahns as Chief Scientific Officer
AQ
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
GL
ALLTRNA EXPANDS LEADERSHIP TEAM WITH APPOINTMENTS OF CHIEF SCIENTIFIC OFFICER AND CHIEF TECHNOLOGY OFFICER
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DNLI Stock
  4. News Denali Therapeutics Inc.
  5. Press Releases